Related Experiment Video
Updated: Nov 3, 2025
A Fluorescence-based Assay for Characterization and Quantification of Lipid Droplet Formation in Human Intestinal Organoids
Published on: October 13, 2019
Diacylglycerol Kinase alpha in X Linked Lymphoproliferative Disease Type 1
Suresh Velnati1,2, Sara Centonze1,2, Federico Girivetto1,2
1Department of Translational Medicine, University of Piemonte Orientale, 28100 Novara, Italy.
Abstract:
Diacylglycerol kinases are intracellular enzymes that control the balance between the secondary messengers diacylglycerol and phosphatidic acid. DGKα and DGKζ are the prominent isoforms that restrain the intensity of T cell receptor signalling by metabolizing PLCγ generated diacylglycerol. Thus, their activity must be tightly controlled to grant cellular homeostasis and refine immune responses. DGKα is specifically inhibited by strong T cell activating signals to allow for full diacylglycerol signalling which mediates T cell response. In X-linked lymphoproliferative disease 1, deficiency of the adaptor protein SAP results in altered T cell receptor signalling, due in part to persistent DGKα activity. This activity constrains diacylglycerol levels, attenuating downstream pathways such as PKCθ and Ras/MAPK and decreasing T cell restimulation induced cell death. This is a form of apoptosis triggered by prolonged T cell activation that is indeed defective in CD8+ cells of X-linked lymphoproliferative disease type 1 patients. Accordingly, inhibition or downregulation of DGKα activity restores in vitro a correct diacylglycerol dependent signal transduction, cytokines production and restimulation induced apoptosis. In animal disease models, DGKα inhibitors limit CD8+ expansion and immune-mediated tissue damage, suggesting the possibility of using inhibitors of diacylglycerol kinase as a new therapeutic approach.
Insights
Diacylglycerol kinases (DGKα) regulate T cell receptor signaling. Inhibiting DGKα in X-linked lymphoproliferative disease 1 restores T cell function and offers a potential therapeutic strategy.
Area of Science:
- Immunology
- Molecular Biology
- Enzymology
Background:
- Diacylglycerol kinases (DGKs) are crucial intracellular enzymes regulating diacylglycerol (DAG) and phosphatidic acid levels.
- DGKα and DGKζ isoforms are key regulators of T cell receptor (TCR) signaling intensity.
- Tight control of DGK activity is essential for immune homeostasis and response refinement.
Purpose of the Study:
- To investigate the role of DGKα in T cell signaling and its dysregulation in X-linked lymphoproliferative disease 1 (XLP1).
- To explore the therapeutic potential of DGKα inhibition in restoring T cell function and mitigating immune pathology.
Main Methods:
- Analysis of T cell signaling pathways, including diacylglycerol metabolism and downstream effectors like PKCθ and Ras/MAPK.
- Assessment of T cell restimulation-induced apoptosis in patient-derived cells and animal models.
- Evaluation of the effects of DGKα inhibitors on T cell responses and immune-mediated tissue damage.
Main Results:
- Persistent DGKα activity in XLP1 leads to attenuated TCR signaling, reduced downstream pathway activation, and defective T cell restimulation-induced apoptosis.
- Inhibition or downregulation of DGKα activity in vitro restores normal diacylglycerol signaling, cytokine production, and apoptosis.
- DGKα inhibitors demonstrated efficacy in animal models by limiting CD8+ T cell expansion and immune-mediated tissue damage.
Conclusions:
- DGKα plays a critical role in modulating TCR signaling and T cell apoptosis, with its dysregulation contributing to XLP1 pathology.
- Targeting DGKα activity represents a promising therapeutic avenue for XLP1 and potentially other immune-mediated disorders.
Related Concept Videos
01:22Amplifying Signals via Enzymatic Cascade
01:11IP3/DAG Signaling Pathway
01:22Lysosomal Hydrolases